Likewise, other oncogene-addicted NSCLC patients progressing under ALK or ROS1 tyrosine kinase inhibitors were shown to benefit from the optimization of subsequent treatment strategies based on ctDNA characterization [42,65,69]. Here, ALK is linked to non-small cell lung carcinoma.